Automation Workflow for Parallel Molecular Series Expansion

Manual analog design is a sequential, chemist-intensive bottleneck. This workflow automates the generation, filtering, and prioritization of analogs for multiple hit series simultaneously. By orchestrating rule-based and AI-driven transformations, property filters, and synthesis scoring in parallel tracks, it compresses the design phase from months to weeks. The throughput gain allows teams to explore a wider structural landscape per series, converging on optimal leads faster and shortening the critical path to preclinical candidate selection.

Up to 30% of proposed analogs have poor synthesizability or require exotic reagents, leading to wasted chemistry effort. The workflow integrates a retrosynthesis planning agent that scores every generated structure for synthetic feasibility, step count, and reagent availability against internal inventory. By front-loading this filter, it ensures the final prioritized list is grounded in practical chemistry. This prevents costly dead-end synthesis attempts, improves chemistry team utilization, and protects the budget allocated for compound procurement and synthesis.

Human-driven design can be biased and miss optimal regions of chemical space. The automated workflow applies systematic, multi-parameter optimization (MPO) across all parallel series. It balances potency, selectivity, ADMET, and physicochemical properties according to a defined target profile, using objective scoring to rank analogs. This data-driven approach reduces subjective debate, surfaces non-obvious structural improvements, and systematically drives each series toward a higher-quality, more developable chemical space, de-risking downstream development.

Manually checking thousands of analogs against global patent databases is impractical. An integrated IP mining agent automatically screens all generated structures against patent corpora and internal libraries to flag freedom-to-operate (FTO) risks. This enables proactive design around competitor claims and identifies white space for novel, patentable chemistry. The result is a stronger, more defensible IP position for each lead series and a reduced risk of costly late-stage patent challenges.

The workflow acts as a force multiplier for medicinal chemistry teams. By automating the repetitive tasks of analog ideation, property calculation, and initial prioritization, it allows senior chemists to focus on high-value strategic decisions, complex problem-solving, and experimental validation. This operational leverage lets a single team manage multiple parallel optimization campaigns effectively, increasing portfolio throughput without a proportional increase in FTEs, directly improving R&D operating economics.

Ad-hoc design processes lack traceability, making it hard to reproduce or justify decisions. This orchestrated workflow, built on frameworks like LangGraph, creates a complete audit trail. Every design decision, filtering step, and prioritization score is logged, linking final compound selections back to the initial hypotheses and constraints. This reproducibility is critical for internal governance, regulatory inquiries, and transferring projects between teams, turning molecular design from an art into a standardized, defensible engineering discipline.

This core agent ingests the core hit series scaffolds and applies a library of rule-based (e.g., bioisosteric replacements) and AI-driven (generative graph model) transformations to propose structural analogs. It manages parallel design tracks, ensuring each series is explored systematically without cross-contamination of chemical logic. The agent outputs a raw candidate list tagged by parent series and transformation type for downstream filtering.

A decision engine that applies a cascade of predictive models to score and filter the raw analog list. It sequentially evaluates drug-likeness (e.g., Lipinski's Rule of 5), predicted ADMET properties, synthetic accessibility, and novelty against internal and external compound databases. Candidates failing critical thresholds (e.g., predicted hERG liability) are automatically culled, ensuring only viable, profile-aligned molecules proceed.

This agent bridges digital design and physical synthesis. For each prioritized analog, it uses a retrosynthesis AI (e.g., ASKCOS, IBM RXN) to propose 1-3 synthetic routes. It scores each route for step count, expected yield, reagent cost, and availability against an integrated vendor/inventory database. The final output is a synthesis-ready candidate list with associated routes and purchasable building blocks, directly feeding procurement or internal lab systems.

Built on a framework like LangGraph or Prefect, this layer manages the entire workflow's state, data flow, and error handling. It triggers parallel agent execution, manages job queues for compute-intensive predictions (e.g., cloud-based docking), handles exceptions (e.g., a failed model call), and ensures auditability by logging every decision point. It provides the API endpoints and webhook integrations to connect with ELNs (e.g., Benchling), compound registries, and inventory management systems.

Before synthesis orders are placed, the workflow routes the final candidate list and supporting data (predicted properties, routes) to a configured approval gateway. This is typically a dashboard integrated with Slack or Teams where project chemists and team leads can review, comment, and approve/reject candidates. The orchestration layer only proceeds with approved molecules, ensuring expert oversight is embedded in the automated process.

Production-grade implementation requires secure, bidirectional connectors to enterprise systems. These agents handle: 1) ELN Integration: Pushing final candidate structures and associated data to electronic lab notebooks (e.g., IDBS, Dotmatics). 2) Inventory/Procurement: Generating purchase orders for vendor compounds or reserving internal building blocks. 3) Project CRM: Updating project status and candidate lists in systems like Veeva CRM to maintain portfolio visibility.